Want to join the conversation?
$FISV 2Q15 Call: We are increasingly optimistic about the opportunities ahead. We delivered another quarter of solid results including 4% internal revenue growth, strong margin expansion, and excellent free cash flow. Importantly, our results were in line with our plans and we remain on-track to achieve our full year financial performance outlook.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.